Rob Maguire

Rob Maguire has extensive experience in the pharmaceutical industry, with their most recent position being Director of Chemistry at Cybrexa Therapeutics since October 2019. Prior to that, they worked as a Consultant in Medicinal and Synthetic Chemistry at Thames Pharma Partners LLC from July 2019 to October 2019. From July 2018 to December 2018, Rob held the role of Director of Research and Development at Nalas Engineering Services, Inc.

Rob's earlier experience includes various roles at Pfizer from 1997 to 2018. Rob started as a Senior Scientist in Cardiovascular and Neuroscience Medicinal Chemistry and later became a Principal Scientist in Antibacterials, Immunology, and Inflammation. Subsequently, they served as an Associate Director in the Lead Generation Group and then as a Senior Principal Scientist in Cardiovascular and Metabolic Diseases. Rob also played a significant role in the development of the Synthetic Technology Group and later the Applied Synthesis Technology Group as an Associate Research Fellow. Throughout their career at Pfizer, they contributed to the discovery and development of several high-profile therapeutic targets.

Rob Maguire has a diverse education history spanning several institutions and fields of study. In 1988, they began their undergraduate studies at The University of Manchester, where they earned a Bachelor of Science (BS) degree in Chemistry in 2001. Following this, Maguire pursued further education, obtaining a Master of Science (MS) degree in Synthetic Organic Chemistry from The University of Manchester in 1992. In 1991, they also embarked on a Doctor of Philosophy (PhD) program at The University of Manchester, specializing in Synthetic Organic Chemistry, which they completed in 1995. During their doctoral studies, Maguire engaged in post-doctoral research at Frei Universitat - Berlin/JW Goethe Universitat - Frankfurt from 1995 to 1996, focusing on the induction of 1,4-diastereoselectivity in the Nozaki-Hiyama Allylation Reaction. Furthermore, in 1996, they pursued additional post-doctoral research at Université de Montréal, specializing in the synthesis of azetidine-2-carboxylic acids from diastereoselective allylation of oximes. Continuing their commitment to professional development, Maguire obtained a Project Management Certificate from Cornell University in 2019.